13 Mar 17

About the companyProgenics Pharmaceuticals, Tarrytown, is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Client programs for gastroenterology, virology, including human immunodeficiency virus and hepatitis C virus infections – directed and oncology. Progenics, in collaboration with Wyeth, sufficient more . Relistor for the treatment of opioid – induced side effects. In the U.S., RELISTOR subcutaneous injection for the treatment of opioid-induced constipation in patients with advanced illness response to palliative care when response to laxative therapy has not been shown sufficient. In Canada, RELISTOR for subcutaneous administration for the treatment of OIC in patients with advanced disease In palliative care. In EU Member States, Norway and Liechtenstein, RELISTOR subcutaneous injection for the treatment of OIC in patients with advanced illness who are receiving palliative care when response to usual laxative therapy has not been given sufficient. Account submissions for RELISTOR in Australia and other countries. PRO 140 is currently in Phase 2 clinical trials. Pre – clinical programs for the development of novel HCV entry inhibitors are also underway. In the field of oncology, the Company is developing a human monoclonal antibody-drug conjugate for the treatment of prostate cancer – a selectively targeted cytotoxic antibody against prostate specific membrane antigen is addressed. PSMA is a protein on the surface of prostate cancer cells and is found in the blood vessels supplying other solid tumors. Progenics and the development of and the development of vaccines to treat prostate cancer by stimulating an immune response against PSMA.

Risks and uncertainties including general economic conditions including interest and currency exchange rate fluctuations and the availability of capital, changes in generally accepted accounting principles, the impact of laws and regulatory requirements, the highly regulated nature of our business, including government cost-cutting initiatives and restrictions on third-party payments for our products, trade buying patterns, the competitive environment in our industry, and other factors described in our Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission Commission. In particular we can not guarantee that RELISTOR will be commercially successful or be approved in the future in other formulations, indications or jurisdictions, or that any of our other programs in a commercial product in a commercial product. Forward-looking policy of updating or revising forward-looking statements and assumes no obligation to update looking statements due to new information or future events or developments. Therefore, one should not assume that our silence over time means that actual events be from which, as expressed or implied forward-looking statements are.

fda website

In an attempt to encourage more at-risk persons on be subjected to HIV testing, the Ministry of Health is adding four private hospitals its latest list of anonymously HIV tests hospitals provide merely three clinics in currently anonymous tests. The new hospitals will start to testing on 1st November.

The brain is damage can result from binge drinking also early and to head trauma personal injury may have been caused. This is not to say that all the repeated infringement has brain injury, but of you of them what we perhaps expect to to be among the general population comparing Dr. Brown told a parliamentary committee start of this year.